Mineralys Therapeutics Inc $MLYS

Recent News (6)

• Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference GlobeNewswire · 26 Aug 2026 RADNOR, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related…
• Mineralys Therapeutics CCO Eric Warren sells $193,188 in shares Investing.com · 25 Aug 2026 Mineralys Therapeutics CCO Eric Warren sells $193,188 in shares
• Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · 13 Aug 2026 RADNOR, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related…
• Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire · 11 Aug 2026 – PDUFA target date of December 22, 2026 for lorundrostat; commercial preparations on-track for launch upon approval –
• Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026 GlobeNewswire · 04 Aug 2026 RADNOR, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related…
• Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · 27 Jul 2026 RADNOR, Pa., July 27, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-relate…